SEC Form 4 · accession 0001171000-15-000070
Nexvet Biopharma plc · NVET
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Colin Giles
Officer — VP Clinical&Regulatory Affairs
Period of report
Sep 3, 2015
Accepted (ET)
Sep 8, 2015 · 2:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618561
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF1 | $0.125 | Sep 3, 2015 | A | 16,162 | A | Jul 1, 2016 | Jul 1, 2020 | Ordinary Shares | 16,162 | 16,162 | D |
Explanation of responses
- F14,041 of the Restricted Share Units shall vest and become convertible on each of 7/1/16 and 7/1/17 and 4,040 of the Restricted Share Units shall vest and become convertible on each of 7/1/18 and 7/1/19, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.